Royal Bank of Canada
BCAX

Royal Bank of Canada’s Bicara Therapeutics BCAX Stock Holding History

Royal Bank of Canada’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2K Sell
80
-1,002
-93% -$17.2K ﹤0.01% 6785
2025
Q4 		$18K Buy
1,082
+671
+163% +$11.5K ﹤0.01% 6127
2025
Q3 		$7K Sell
411
-6,669
-94% -$74.7K ﹤0.01% 6616
2025
Q2 		$65K Buy
7,080
+6,215
+718% +$74.1K ﹤0.01% 5804
2025
Q1 		$11K Sell
865
-659
-43% -$8.75K ﹤0.01% 6136
2024
Q4 		$26K Buy
1,524
+1,424
+1,424% +$29.6K ﹤0.01% 6009
2024
Q3 		$3K Buy
+100
New +$2.55K ﹤0.01% 6622

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Royal Bank of Canada's BCAX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Bicara Therapeutics (BCAX) stake by 93% in Q1 2026, selling an estimated $17.2K and leaving 80 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #6785.

Royal Bank of Canada first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. The position peaked at $65K in Q2 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Royal Bank of Canada held 80 shares of Bicara Therapeutics worth $2K as of Q1 2026.
  • Royal Bank of Canada sold 1,002 Bicara Therapeutics shares in Q1 2026, an estimated $17.2K.
  • Bicara Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6785 holding.
  • Royal Bank of Canada first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Royal Bank of Canada's Bicara Therapeutics position peaked at $65K in Q2 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.